AZN Jan 2026 77.500 put
- Bloomberg
Goldman Sachs Says Buy European Pharma Stocks Touting Innovation
(Bloomberg) -- European drugmakers that are focused on building portfolios of new medicines have gotten a nod from analysts at Goldman Sachs Group Inc.Most Read from BloombergWorld’s Largest Nuclear Plant Sits Idle While Energy Needs Soar‘Not Gonna Be Pretty:’ Covid-Era Homebuyers Face Huge Rate JumpWarning Signals Are Flashing for Homeowners in Texas and FloridaInsurers Sink as UnitedHealth Sees ‘Disturbance’ in MedicaidAmerican Air Fired Commercial Head After Sales Strategy Alienated Corporate
- Zacks
AstraZeneca (AZN) Falls on Failure to Meet NSCLC Study OS Goal
AstraZeneca's (AZN) shares decline as it fails to achieve statistically significant overall survival data in a late-stage NSCLC study on Dato-DXd compared with docetaxel.
- GlobeNewswire
Cellectis Reports Financial Results for First Quarter 2024
• Cellectis announced completion of the additional equity investment of $140M by AstraZeneca • Cash position of $143 million as of March 31, 20241; cash runway projection into 20262 • Conference call and webcast scheduled for tomorrow, May 29, 2024 at 8:00AM ET / 2:00PM CET NEW YORK, May 28, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and g
